| Tekturna (aliskiren) / PDL |
| Completed | 2 | 445 | Japan | Aliskiren | Novartis | Hypertension | 03/05 | 03/05 | | |
NCT00097955: Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria |
|
|
| Completed | 2 | 496 | US, Canada, Europe, RoW | aliskiren | Novartis Pharmaceuticals | Diabetic Nephropathy | 04/07 | 04/07 | | |
NCT00409578 / 2006-001763-36: Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome |
|
|
| Completed | 2 | 1101 | US, Canada, Europe, RoW | Placebo, Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg | Novartis, The TIMI Study Group | Post Acute Coronary Syndrome, Myocardial Ischemia | 04/09 | 04/09 | | |
| Completed | 2 | 68 | Europe, RoW | Aliskiren, Valsartan, Placebo to aliskiren, Placebo to valsartan | Novartis | Hypertension | 10/09 | 10/09 | | |
NCT00939588: Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients |
|
|
| Completed | 2 | 88 | RoW | Aliskiren/ Valsartan, Telmisartan/ Ramipril | Novartis Pharmaceuticals | Hypertension | 12/09 | | | |
NCT00417170: Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome |
|
|
| Completed | 2 | 48 | US | Aliskiren, Amlodipine, Placebo Aliskiren, Placebo Amlodipine | Novartis Pharmaceuticals | High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction | 07/10 | 07/10 | | |
| Terminated | 2 | 31 | Europe | Aliskiren/amlodipine, SPA100, Amlodipine, Placebo to Aliskiren/amlodipine, Placebo to Amlodipine | Novartis Pharmaceuticals | Hypertension, Ankle Edema | 11/10 | 11/10 | | |
NCT00498433 / 2005-004566-16: Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension |
|
|
| Terminated | 2 | 46 | Europe | Aliskiren, SPP100, Amlodipine, Placebo of Aliskiren, Placebo of amlodipine | Novartis | Hypertension, Abdominal Obesity | 03/12 | 03/12 | | |
NCT01480791: Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries |
|
|
| Withdrawn | 2 | 0 | Canada | Aliskiren vs. hydrochlorothiazide, Aliskiren is Tekturna or Rasilez, Hydrochlorothiazide, Hydrochlorothiazide is a generic drug. | Sir Mortimer B. Davis - Jewish General Hospital, Novartis Pharmaceuticals | Hypertension, Diabetes | 12/13 | 12/13 | | |
NCT00834041 / 2008-005802-37: A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age |
|
|
| Completed | 1/2 | 39 | US, Europe, RoW | Aliskiren 3.125 mini-tablets | Novartis | Hypertension | 01/10 | 01/10 | | |
